TRANSLATIONAL INDEX
LIVE

Serial Number

97882540

Owner

VeriSIM Life Inc.

Attorney

Norm J. Rich

First Use Date

Sep 30, 2022

Filing Date

Apr 11, 2023

Add to watchlist:

No watchlists yet
View on USPTO

TRANSLATIONAL INDEX Trademark

Serial Number: 97882540 • Registration: 7504463

TRANSLATIONAL INDEX is a trademark filed by VeriSIM Life Inc. on April 11, 2023. The trademark is classified under Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

VeriSIM Life Inc. (2 trademarks)

1 Sansome Street, Suite 3500
San Francisco, CA 94104

Entity Type: 03

Trademark Details

Filing Date

April 11, 2023

Registration Date

September 10, 2024

First Use Anywhere

September 30, 2022

First Use in Commerce

September 30, 2022

Goods & Services

Software as a service (SAAS) services featuring software for modeling, rating, scoring and reporting on the conducting of simulations and predictions of properties of drugs or chemicals or vaccines including absorption, release rate, bioavailability, pharmacokinetics and pharmacodynamics, safety, toxicology, and efficacy profiles, routes of administration, and dose optimization; Software as a service (SAAS) services featuring software that allows for the simulation, prediction, rating, scoring, and reporting of drug-to-drug interactions; Software as a service (SAAS) services featuring software for the simulation, prediction, rating, scoring, and reporting of drug or vaccines or chemical effects on animals and virtual animal or patient populations; Software as a service (SAAS) services featuring software which allows researchers to adjust pharmacodynamic models to observed data and to then use the resulting fitted models to simulate, predict, rate, score, and report on pharmacodynamic changes due to changes in routes of administration, dose, dosage form, and dosing regimen of a drug or chemical or vaccine; Software as a service (SAAS) services featuring software which allow for the prediction, rating, scoring, and reporting of absorption and systemic distribution/elimination for large molecules; Software as a service (SAAS) services featuring software that incorporates artificial intelligence and machine learning to simulate, predict, rate, score, and report on the clinical efficacy of new drugs or chemicals or or vaccines before human trials and accelerate pharmaceutical drug or vaccine development and regulatory approval

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 10, 2024 NRCS
REGISTERED-SUPPLEMENTAL REGISTER
Sep 10, 2024 R.SR
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Aug 2, 2024 CNTA
EXAMINER'S AMENDMENT ENTERED
Aug 2, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 2, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 2, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 2, 2024 CNEA
USE AMENDMENT ACCEPTED
Aug 2, 2024 IUAA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 30, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 30, 2024 CRFA
ASSIGNED TO LIE
Jul 30, 2024 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 9, 2024 TROA
AMENDMENT TO USE PROCESSING COMPLETE
Feb 8, 2024 AUPC
USE AMENDMENT FILED
Feb 8, 2024 IUAF
TEAS AMENDMENT OF USE RECEIVED
Feb 8, 2024 EAAU
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 8, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 8, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 8, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 8, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 5, 2023 NWOS
NEW APPLICATION ENTERED
Apr 14, 2023 NWAP